TICKERNERD
Menu
SLPSLPHealthcare · Health Information Services

SLP Stock Forecast: Simulations Plus, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$19
0.00% on the day

The 2 Wall Street analysts covering Simulations Plus, Inc. hold a median 12-month price target of $19 — +0.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 6 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$374.2M
Ticker Nerd rank
79 / 100
Median analyst target
$19
Analysts covering
2
Revenue$21.9M+7.5% y/y
Operating income$4.5M
Net income$3.6M
Free cash flow$7.9M
Quarterly, 8 quarters to 31 May 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.1%
1M
+0.4%
YTD
+1.5%
1Y
+15.5%
From 52W high
−11.2%
From 52W low
+62.9%
$11
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SLP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Simulations Plus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
88
Growth
86
Momentum
71
Issuance
69
Quality
66
Size
57
Value
54
Revisions
39
Volatility
38

Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (38): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SLP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$12$14$16$18$20$22Jan 26Apr 26Jul 26Oct 26SLPHigh $19Median $19Low $19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
0 Buy2 Hold0 Sell
Low $19Median $19High $19

The green dot is the last close — the median target sits 0.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 June 2026William BlairDowngradeMarket Perform—
10 Apr 2026TD CowenMaintainsHold—
8 Jan 2026TD CowenMaintainsHold—
18 Dec 2025BTIGDowngradeNeutral—
30 Sept 2025TD CowenInitiatesHold—
15 July 2025KeybancDowngradeSector Weight—
15 July 2025Stephens & Co.MaintainsOverweight—
14 July 2025KeybancMaintainsOverweight—
7 July 2025BTIGMaintainsBuy—
18 June 2025JMP SecuritiesReiteratesMarket Perform—
13 June 2025Craig-HallumMaintainsBuy—
16 Apr 2025KeybancMaintainsOverweight—
24 Jan 2025KeybancMaintainsOverweight—
8 Jan 2025KeybancMaintainsOverweight—
15 Nov 2024Stephens & Co.InitiatesOverweight—
6 Nov 2024William BlairReiteratesOutperform—
24 Oct 2024BTIGMaintainsBuy—
24 Oct 2024William BlairReiteratesOutperform—
12 Sept 2024William BlairReiteratesOutperform—
29 July 2024KeybancInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SLP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Simulations Plus, Inc. returned +15.5% against +17.0% for the S&P 500, dividends included.

SLP vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Jan 26Apr 26Jul 26Oct 26SLPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SLP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
0.0%
Analysts raising
1
Analysts cutting
5
Fundamentals

Simulations Plus, Inc. (SLP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
46.3×

Cheaper than 16% of US stocks

Price / sales
4.6×

Cheaper than 26% of US stocks

Price / book
2.7×

Cheaper than 34% of US stocks

EV / EBITDA
21.6×

Cheaper than 14% of US stocks

Growth & margins
Revenue growth (YoY)
7.5%

Higher than 45% of US stocks

Earnings growth (YoY)
7.5%

Higher than 44% of US stocks

Gross margin
69.1%

Higher than 82% of US stocks

Operating margin
22.8%

Higher than 82% of US stocks

Net margin
9.9%

Higher than 70% of US stocks

Returns & dividend
Return on equity
6.2%

Higher than 55% of US stocks

Return on assets
5.5%

Higher than 79% of US stocks

Dividend yield
1.3%

Higher than 73% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Simulations Plus, Inc. (SLP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Simulations Plus, Inc. has a market value of $374.2M and an enterprise value of $324.7M.

  • Revenue in the twelve months to 31 May 2026: $82.1M. The latest quarter grew 7.5% year on year.

  • Net income over the same four quarters: $8.1M, a 9.9% net margin.

  • Free cash flow in the twelve months to 31 May 2026: $21.7M, after $2.9M of capital spending.

  • Shares outstanding: 20.2M.

  • Trailing P/E: 46.3×; forward P/E: 20.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.30%, paying out 0% of earnings.

  • Simulations Plus, Inc. employs 212 people — $387K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 May 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

SLP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
SLPSimulations Plus, Inc.$374.2M
79
CARLCarlsmed, Inc.$401.8M
33
CTEVClaritev Corp.$412.3M
64
NRCNRC Health$460.0M
90
EVHEvolent Health, Inc.$474.5M
61
WEAVWeave Communications, Inc.$590.4M
81
SOPHSOPHiA GENETICS SA$605.7M
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Simulations Plus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SLP news & analysis

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

Business Wire · 8 Oct 2026positive

Simulations Plus announced a funded partnership with a global pharmaceutical company to apply its AI-enabled QSP engine, Turin, in an active therapeutic development program. The collaboration will evaluate the application of AI-enabled QSP modeling.

Why it matters — The partnership highlights a funded industry application of Simulations Plus’ Turin platform in drug development.

Simulations Plus Announces Completion of Acquisition by Altaris

Business Wire · 6 Oct 2026neutral

Simulations Plus announced that affiliates of Altaris, an investment firm focused exclusively on healthcare, have completed their acquisition of the company. The transaction was originally announced on June 16, 2026.

Why it matters — The completion marks a change in ownership for Simulations Plus, relevant to investors following the company.

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

Business Wire · 17 Sept 2026positive

Simulations Plus announced that the FDA's Cosmetics Regulatory Science Branch has licensed its ADMET Predictor® software for computational research supporting modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology within the FDA.

Why it matters — This new FDA license extends adoption of Simulations Plus technology into a new regulatory area, signaling broader institutional use of its software.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Newsfile Corp · 15 Sept 2026negative

Johnson Fistel, PLLP announced it is investigating Simulations Plus, Inc. (NASDAQ: SLP) on behalf of investors who suffered losses, following the company's revenue guidance cut and accounting disclosures. The investigation concerns whether investors may recover losses under federal securities laws.

Why it matters — SLP watchers will care because the investigation signals potential legal and regulatory scrutiny tied to the company's revenue guidance reduction and accounting disclosures, which may affect investor confidence.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

GlobeNewsWire · 10 Sept 2026negative

Johnson Fistel, PLLP announced it is investigating Simulations Plus, Inc. (NASDAQ: SLP) on behalf of investors who suffered losses, following the company's revenue guidance cut and accounting disclosures. The firm is looking into whether investors may recover losses under federal securities laws.

Why it matters — SLP watchers would care because the investigation highlights investor concerns tied to the company's recent revenue guidance cut and accounting disclosures.

FAQ

Frequently asked questions about SLP stock

What is the SLP stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Simulations Plus, Inc. have a median 12-month price target of $19, with estimates ranging from $19 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SLP stock a buy right now?

Of the 2 analysts covering Simulations Plus, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Simulations Plus, Inc. 79 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SLP?

As at 6 Oct 2026, Simulations Plus, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).

Will SLP stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +0.0% from the last close, and Ticker Nerd's factor model ranks Simulations Plus, Inc. 79 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SLP stock forecast for 2030?

No analyst covering Simulations Plus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $19 over the next 12 months.

How has SLP stock performed over the past year?

Simulations Plus, Inc. returned +15.5% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Simulations Plus, Inc. do?

Simulations Plus Inc. is a healthcare technology company that develops modeling and simulation software and consulting services for the pharmaceutical, biotechnology, and life sciences industries.

What is the latest news on SLP?

The most recent item we track (Business Wire, 8 Oct 2026): "Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin". Simulations Plus announced a funded partnership with a global pharmaceutical company to apply its AI-enabled QSP engine, Turin, in an active therapeutic development program. The collaboration will evaluate the application of AI-enabled QSP modeling.

Company

About Simulations Plus, Inc.

Simulations Plus Inc. is a healthcare technology company that develops modeling and simulation software and consulting services for the pharmaceutical, biotechnology, and life sciences industries. The company’s products help customers support drug discovery, preclinical research, clinical development, regulatory submissions, and commercialization by improving how drug behavior and molecular properties are analyzed. Its software portfolio includes tools used for biosimulation, pharmacokinetic and pharmacodynamic modeling, and prediction of absorption, distribution, metabolism, excretion, and toxicity characteristics. Simulations Plus also provides professional services that complement its software by helping clients apply model-informed approaches across the drug development process. The company serves a global customer base that includes pharmaceutical companies, biotech firms, and research organizations.

212 employees · United States · https://www.simulations-plus.com